

INJUDICIOUS USE OF PROTON PUMP INHIBITORS ON IRREGULAR BASIS WITHOUT PRESCRIPTION – AN ALARMING SITUATION

Shumaila Shaikh¹, Umair Ali Soomro², Muhammad Atif Ata³, Azhar Memon⁴, Kashif Rasheed Shaikh⁵, Shomail Saeed Siddiqui⁶.

ABSTRACT

INTRODUCTION: Proton pump inhibitors (PPIs) are one of widely used drug agents primarily indicated for the acid peptic disorders. **OBJECTIVE:** Determine the Prescription Patterns of Proton Pump Inhibitors (PPI) at the outpatient department (OPD) of a tertiary care hospital of Sindh, **STUDY DESIGN:** Retrospective study, **PLACE AND DURATION:** Department of Pharmacology and Medicine, Peoples University of Medical and Health Sciences for Women from February 2019 to August 2020. **METHODS:** Previous records of 300 outpatient department (OPD) subjects were checked during the study period. OPD sample was selected by probability non – purposive convenient sampling. Age, gender and GI symptoms PPI used for were entered in proforma. PPI class, duration of use, frequency of use, and prescription or non-prescription patterns were noted. Data variables were saved in a pre – structured proforma. Data was analyzed on SPSS (version 21.0) and Microsoft Excel sheet. Data was presented as tables showing frequency and % of variable. **RESULTS:** Omeprazole was used by 31% followed by dexlansoprazole 29%, esomeprazole 21%, pantoprazole 7.3%, lansoprazole 7.6% and rabeprazole by 4% of subject's respectively (table - 2). PPI were being used as long durations as >5 years noted in 18.6% on irregular basis (35.6%) and without prescription (63.0%). **CONCLUSION:** We found injudicious use of proton pump inhibitors on irregular basis without prescription that needs to be controlled by the health authorities.

KEY WORDS: Proton Pump inhibitors, Injudicious Use, Non - prescription

1. Assistant Professor Department of Biochemistry, Khairpur Medical College, Khairpur Mirs, Sindh, Pakistan.
2. Assistant Professor, Department of Hematology, Indus Medical College Tando Muhammad Khan, Sindh, Pakistan.
3. Professor, Department of Biochemistry, Suleman Roshan Medical College, Tando Adam, Sindh, Pakistan.
4. Assistant Professor Department of Medicine, Suleman Roshan Medical College, Tando Adam, Sindh, Pakistan.
5. Associate Professor Department of Pharmacology, Suleman Roshan Medical College, Tando Adam, Sindh Pakistan.
6. Assistant Professor, Department of Pathology, Indus Medical College Tando Muhammad Khan, Sindh, Pakistan.

How to cite this article: Soomro UA¹, Shaikh S², Ata MA³, Memon A⁴, Shaikh KR⁵, Siddiqui SS⁶. **INJUDICIOUS USE OF PROTON PUMP INHIBITORS ON IRREGULAR BASIS WITHOUT PRESCRIPTION – AN ALARMING SITUATION.** *JPUMHS*; 2021;11:03, 78-82. <http://doi.org/10.46536/jpumhs/2021/11.03.320>

For Correspondence: Dr Kashif Rasheed Shaikh MBBS, M. Phil Associate Professor Department of Pharmacology, Suleman Roshan Medical College, Tando Adam, Sindh, Pakistan
Email: mailboxxm@gmail.com

Received July 14th 2021, Accepted On 15th September 2021, Published On 30th September 2021

INTRODUCTION

Proton pump inhibitors (PPIs) are one of widely used drug agents primarily indicated for the acid peptic disorders. It is the widely purchased by prescription but more so non-prescription as over the counter drugs that is illegal. PPIs are prescription sold drug agents only despite this is available freely.^{1,2} Although PPIs are an excellent drug of its class but injudicious use has created problem of toxicity and adverse drug reactions. PPIs

are indicated for the acid peptic disorders, gastro-esophageal reflux disease (GORD), gastric and duodenal ulcers, Zollinger – Ellison syndrome (ZES), esophageal ulceration, and Barrett's esophagus. Maintenance low dose PPIs prevents the recurrence of acid related disorders of upper GI system. PPIs have shown promising results in the eradication of H.pylori. PPIs are now over-prescribed and over – used for gastric acid disorders. PPIs are also indicated

as co-therapy for nonsteroidal anti-inflammatory drug (NSAID) and aspirin. Injudicious uses are frequent for the functional dyspepsia, mild gastric problems, and un-investigated dyspepsia without making a proper diagnosis. Non-ulcer dyspepsia (NUD) or with mild dyspepsia are often not benefited from PPIs but still people are using without prescription.^{2,3} It has noted the majority of patients attending the OPDs have already used a variety of PPIs before reaching to the medical officers. Masses are using the high dose PPIs for poorly defined gastric problems or as digestant after hot spicy foods that has become a public dilemma. Such inappropriate and injudicious PPIs use has accelerated adverse effects that are unnoticed and not understood properly creating new health problems and are threatening normal health of public. Currently, the PPIs are the over used by prescription and non-prescription.⁴⁻⁵ Many subjects are taking the drug as self-determined regimen on irregular basis.^{6,7} Although intermittent therapy with H₂-blockers is ideal and considered safe but is denied. In general, a pressure is developed by the pharmaceutical industry on the general practitioners (GPs) to prescribe the PPIs to each of the patient 'inappropriately'.⁸ PPIs have side effects as diarrhea, gut upset, headache and malabsorption. Headache and diarrhea are noted in up to 10% subjects. PPIs use is linked to increased risk of malabsorption, vitamin and iron deficiency, bacterial growth, community acquired pneumonia, C – difficile colitis and C – jejuni gastroenteritis.^{7,8} PPIs interact with vitamin, mineral, calcium supplements and occasionally cause adverse drug reactions resulting in hepatic, renal, bone marrow, skin and even anaphylaxis.⁹⁻¹¹ Data is lacking on the injudicious use of PPIs, patterns of its use, duration and side effects. National data is seriously lacking although the problem has deep rooted. In this context, the present observations study was conducted on the dose and duration of proton pump inhibitors in the general patient population. The present study determined the clinical and practice use on PPIs use, duration of uses, dosing frequency and prescription patterns in patients attending the OPD of our tertiary care hospital.

METHODOLOGY

The present retrospective study took place at the Department of Pharmacology and Medicine, Peoples University of Medical and Health Sciences for Women from February 2019 to August 2020. Study protocol was discussed in detail by the researchers.

Hundreds of patients were screened as per inclusion criteria. Inclusion criteria were records of drug prescriptions, laboratory investigations, outpatient department (OPD) patients, complete clinical history, PPIs intake irrespective of duration, and age 40 – 60 years. Finally, 300 patients qualified the inclusion criteria and were included in the study protocol. Patients were selected according to the convenient sampling. Patients with major systemic disease such as; chronic liver diseases, chronic lung disease, chronic valvular cardiac disease, chronic malabsorption syndrome, pulmonary tuberculosis, etc. were excluded. Patients without proper records and prescription slips were also excluded. Volunteers were interviewed that the participation is on personal willingness, and there will be no extra expenses of any investigations. They were taken into confidence that if they are not willing, it will not affect their therapy. Patients with proofs of PPIs intake of different symptoms and durations were further screened. Symptoms of PPIs intake were confirmed by interviews and from prescription records. Clinical history of epigastric pain, heart burn, dyspepsia, nausea, vomiting, hematemesis, indigestion, bloating and retching (34.3%) was taken in detail. Age, gender, PPIs class, duration of PPIs, frequency of PPIs (regular or irregular intake) use, and prescription or non – prescribed, were noted in a pre – structured proforma. Type of PPIs taken was enquired and checked from prescriptions and included; omeprazole, esomeprazole, pantoprazole, dexlansoprazole, lansoprazole and rabeprazole. PPIs intake details were saved in the proforma. Saved data in proforma was kept confidential. The data was copied and pasted on Microsoft Excel Sheet. Statistical analysis was performed on Statistical Package for Social Sciences (SPSS) 21.0 (ver.) (Microsoft Windows Release) (IBM, Inc., Chicago, IL, USA) using Student's t – test and Chi – square testing. Result output of continuous data was presented as mean±SD. And results of Categorical data were presented as frequency and %. Analysis of significance was calculated at 95% CI (P ≤ 0.05).

RESULTS

Table –1 show age distribution and gender patterns of study subjects (n=300). 21 (7%) subjects belonged to 2nd decade, 53 (17.6%) to 3rd decade, 67 (22.3%) to 4th decade, 45 (15%) to 5th decade, 77 (25.6%) to 6th decade and 37 (12.3%) to ≥6 decade. Mean±SD age was noted as 47.1±10.5 years. Male to female ratio was 1:1, comprised 150 of each gender.

PPI were being used for the epigastric pain (79.6%), heart burn (95.6%), dyspepsia (44%), nausea (13%), vomiting (25.3%), hematemesis (29.6%), indigestion (65.6%), bloating (18.6%) and retching (34.3%). Omeprazole was used by 31% followed by dexlansoprazole 29%, esomeprazole 21%,

pantoprazole 7.3%, lansoprazole 7.6% and rabeprazole by 4% of subject's respectively (table - 2). PPI were intake for long durations as >5 years noted in 18.6% (Table - 3) on irregular basis (35.6%) and without prescription (63.0%).

Table 1. Age and gender distribution of study groups (n=300)

Age (years)	Frequency	%	P
	21	7.0	0.001
	53	17.6	
- 12 – 19.9	67	22.3	
- 20 – 29.9	45	15	
- 30 – 39.9	77	25.6	
- 40 – 49.9	37	12.3	
- 50 – 59.9			
- ≥60			
Gender	150	50%	0.91
- Male	150	50%	
- Female			

Table 2. Frequency of GI symptoms (n=300)

	Frequency	%
Epigastric pain	239	79.6
Heart burn	287	95.6
Dyspepsia	132	44.0
Nausea	39	13.0
Vomiting	76	25.3
Hematemesis	89	29.6
Indigestion	197	65.6
Bloating	53	18.6
Retching	103	34.3

Table 3. Information of PPI use (n=300)

PPI Class	Frequency	%
- Omeprazole	93	31.0
- Esomeprazole	63	21.0
- Dexlansoprazole	87	29.0
- Pantoprazole	22	7.3
- Lansoprazole	23	7.6
- Rabeprazole	12	4.0
Duration	32	10.6
- <1 months	31	10.3
- <6 months	67	22.3
- < 1 years	53	17.6
- 1- 2 years	61	20.3
- >2 years	56	18.6
- >5 years		
Frequency of Use		
- Daily	193	64.3
- Irregular	107	35.6
Prescribed Use		
- Prescribed	111	37.0
- Non – prescribed	189	63.0

DISCUSSION

The present observational study was conducted for PPIs use and duration, dosing frequency and prescription patterns in patients attending the out patients department of a tertiary care hospital. In present study, the mean±SD age was noted as

47.1±10.5 years. The findings are in agreement with previous studies.¹²⁻¹⁴ Madi et al¹² found the age of participants was 40–59 years that is highly comparable to our present study. Age finding of present is also consistent with previous studies.^{13,14} Of 300 study participants, 150 were male and female

each showing male to female ratio 1:1. The findings are inconsistent of a recent study¹² that reported majority of patients were male. Reason could be different sample size, different study settings, geographical patterns of health provision and data collection. Equal ratio of male to female is because of although the male the only bread earners, and are tolerating the major stress of life in the setting of economic crisis of corona virus pandemic but female have been at risk of anxiety by staying at home due to financial crisis equally. Peptic ulcer disease is the major indication of PPIs, but the erupting tense financial crisis has created much worry and anxiety that begot the hyperacidity due to stress. In present study, the PPIs were being used for the epigastric pain (79.6%), heart burn (95.6%), dyspepsia (44%), nausea (13%), vomiting (25.3%), hematemesis (29.6%), indigestion (65.6%), bloating (18.6%) and retching (34.3%). The findings are in keeping with previous studies¹²⁻¹⁴ that had mentioned similar acid related gastric problems. In present study, the omeprazole was frequently used PPI found in 31% followed by dexlansoprazole 29%, esomeprazole 21%, pantoprazole 7.3%, lansoprazole 7.6% and rabeprazole by 4% of subject's respectively (table - 2). The findings are in line with previous studies.¹²⁻¹⁶ Madi et al¹² reported omeprazole was frequent prescribed PPIs followed by esomeprazole and pantoprazole. In present study, the dexlansoprazole was found in 29% second to omeprazole; that is because of its new entry as a magical pill that captured major share of PPIs market being new addition to the already available pool of PPIs. Madi et al¹² found 65% use of esomeprazole and pantoprazole that is in contrast to present study. In present study the rabeprazole accounts for 4% prescriptions that are in contrast to only 1% in a previous study.¹² Currently, the burden of PPIs has increased in the society because of stressful life full of financial constraints putting the pocket open to extra expenses. Patterns of PPIs use noted in present study is in agreement with previous studies.¹⁵⁻¹⁹ However, Pendhari et al¹⁴ has produced inconsistent results as they found high use of rabeprazole that is in contrast to present and previous studies.¹²⁻¹⁹ In present study, the PPIs were intake for long durations as for as >5 years noted in 18.6% (Table - 3) on irregular basis (35.6%) and without prescription (63.0%). This is a crucial state of serious concerns. A previous study¹² reported using PPIs for >1 years in 8% of participants. Hence findings are supporting the present study. In present study the without prescription PPIs were found in 63.0% on

irregular basis in 35.6% participants that is an alarming situation. A previous study²¹ reported the stress ulcer prophylaxis was major indication in 77% of the patients who were prescribed PPIs for >1 year. Using PPIs for more than 5 years as noted in present study is beyond the recommended duration of any of medical indications. It is reported the adverse effects of PPIs are substantially increased when PPIs are used for >1 year.¹² The findings are consistent with previous studies.¹⁷⁻²¹ In light of evidence based finding of present study supported by previous literature, it is an alarming situation of PPIs over – and injudicious use that must be condemned. Institutional pharmacovigilance programs and awareness seminars should be arranged for the medical practitioners and non-prescription sale of drugs must be stopped immediately for overcoming the adverse drug reactions of proton pump inhibitors.

CONCLUSION

The present study shows proton pump inhibitors were being used for long durations as >5 years (18.6%) on irregular basis (35.6%) and without prescription (63.0%). The injudicious use of proton pump inhibitors on irregular basis without prescription needs to be controlled by the health authorities urgently. Further studies on the patterns of proton pump inhibitors use are warranted.

ETHICS APPROVAL: The ERC gave ethical review approval

CONSENT TO PARTICIPATE: written and verbal consent was taken from subjects and next of kin

FUNDING: The work was not financially supported by any organization. The entire expense was taken by the authors

ACKNOWLEDGEMENTS: We would like to thank the all contributors and staff and other persons for providing useful information.

AUTHORS' CONTRIBUTIONS: All persons who meet authorship criteria are listed as authors, and all authors certify that they have participated in the work to take public responsibility of this manuscript. All authors read and approved the final manuscript.

CONFLICT OF INTEREST: No competing interest declared.

REFERENCES

1. Rajput MA, Ali F, Zehra T, Zafar S, Kumar G. The effect of proton pump inhibitors on glycaemic control in diabetic patients. *J Taibah Univ Med Sc* 2020; 15(3):218e223.
2. Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review

- and Best Practice Advice from the American Gastroenterological Association. *Gastroenterol* 2017; 152, 706–715.
3. Vakil, N. Prescribing proton pump inhibitors: is it time to pause and rethink? *Drugs* 2012; 72:437–445.
 4. Nehra AK, Alexander JA, Loftus CG, Nehra V. Proton Pump Inhibitors: Review of Emerging Concerns. *Mayo Clin Proc* 2018; 93:240–246.
 5. Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. *Ther Adv Gastroenterol* 2012; 5:219–232.
 6. Yadlapati R, Kahrilas PJ. When is proton pump inhibitor use appropriate? *BMC Med* 2017; 15:36.
 7. Savarino V, Dulbecco P, de Bortoli N, Ottonello A, Savarino, E. The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. *Eur. J Intern Med* 2017; 37:19–24.
 8. Chien LN. Proton pump inhibitors and risk of periampullary cancers-A nested case-control study. *Int J Cancer* 2016; 138:1401–1409.
 9. Schoenfeld, A. J. & Grady, D. Adverse Effects Associated With Proton Pump Inhibitors. *JAMA Intern Med* 2016; 176:172–174.
 10. Cheung KS. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for *Helicobacter pylori*: a population-based study. *Gut* 2018; 67: 28–35.
 11. Xie Y. Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans. *BMJ Open* 2017; 7: e015735.
 12. Madi L, Ahmed Elhada AH, Alrawashdeh H, Ahmed A. Prescribing pattern of proton pump inhibitors in Qatar rehabilitation institute: A retrospective study. *J Res Pharm Pract* 2019; 8:101-4.
 13. Airee RS, Rawal A, Nimmy NJ, Binu KM. Drug use evaluation of proton pump inhibitors in a private tertiary care teaching hospital. *World J Pharm Pharm Sci* 2016; 5:922-30.
 14. Pendhari SR, Joshi KS, Limaye RP. Use of proton pump inhibitors – A drug utilization study. *Indian J Pharm Pharmacol* 2016; 3:88-94.
 15. Wongtrakula W, Charoenngnamb N, Ungprasert P. Use of proton pump inhibitors is associated with a higher risk of pneumonia in cirrhotic patients: a systematic review and meta-analysis. *Ann Gastroenterol* 2020; 33:1-11.
 16. Haastrup PF, Thompson W, Søndergaard J, Jarbøl DE. Side Effects of Long-Term Proton Pump Inhibitor Use: A Review. *Basic Clin Pharmacol Toxicol* 2018; 123 (2):114-121.
 17. Singh A, Cresci GA, Kirby DF. Proton Pump Inhibitors: Risks and Rewards and Emerging Consequences to the Gut Microbiome. *Nutr Clin Pract* 2018; 33(5):614-624. 9.
 18. Spechler SJ. Proton Pump Inhibitors: What the Internist Needs to Know. *Med Clin North Am* 2019; 103(1):1-14.
 19. 19 Haroon M, Yasin F, Gardezi SK, Adeeb F, Walker F. Inappropriate use of proton pump inhibitors among medical inpatients: A questionnaire-based observational study. *JRSM Short Rep* 2013; 4: 2042533313497183.
 20. Boster J, Lowry L E, Bezzant M L, Kuiper B, Surry L. Reducing the Inappropriate Use of Proton Pump Inhibitors in an Internal Medicine Residency Clinic. *Cureus* 2020; 12(1): e6609.
 21. Hasan MQ, Mondal NT, Parvin R, Perveen I. Uses of Proton Pump Inhibitors and Their Prescribing Pattern among the Patients Attending the Out-Patient Department at a Tertiary Care Hospital in Bangladesh. *J Enam Med Coll* 2020; 10 (1): 10-16.